PSD3 links autophagic flux to MHC-I–associated immune modulation in esophageal squamous cell carcinoma
Top Cited Papers
- 18 May 2026
- journal article
- Published by Springer Nature in Apoptosis
- Vol. 31 (6)
Abstract
Esophageal squamous cell carcinoma (ESCC) is characterized by immune evasion and poor clinical outcomes. Autophagy has been implicated in tumor-immune interactions, but the molecular factors linking autophagy-associated processes to immune modulation in ESCC remain incompletely defined. We analyzed PSD3 expression in ESCC tissues and its association with prognosis and MHC-I-related molecules. Protein interactions were assessed by co-immunoprecipitation. Autophagy-associated marker changes, autophagic flux, total MHC-I protein levels, and immune cell infiltration were evaluated following PSD3 knockdown in murine and human ESCC models using Western blotting, tandem fluorescent LC3 reporter assays, immunohistochemistry, and single-cell RNA sequencing. Epistasis analysis was performed by silencing ATG7 following PSD3 knockdown. PSD3 was upregulated in ESCC and associated with unfavorable prognosis. PSD3 knockdown was accompanied by changes in autophagy-associated markers and reduced autophagosome abundance. In KYSE150 cells, tandem fluorescent mCherry-eGFP-LC3B analysis showed that PSD3 silencing impaired autophagic flux. PSD3 co-immunoprecipitated with ATG7, BAG3 and TBK1, supporting its association with autophagy-related protein complexes. PSD3 knockdown increased total MHC-I protein levels and was associated with enhanced immune cell infiltration in syngeneic tumor models. Furthermore, ATG7 silencing following PSD3 knockdown selectively restored HLA-E expression, while HLA-ABC and HLA-F showed no clearly distinguishable change. These findings support a working model in which PSD3 is linked to autophagy-associated immune modulation in ESCC. While additional studies are required to define pathway hierarchy and antigen-presentation function more directly, PSD3 emerges as a candidate molecular node for further mechanistic and translational investigation.Keywords
Funding Information
- Nature Science Foundation of China (82360521, 82260568)
- State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia Fund (SKL-HIDCA-2024-SG3)
- Leading talent project of scientific and technological innovation in Tianshan talents training plan of Xinjiang Uygur Autonomous Region (2022TSYCLJ0031)
- Key Project of Xinjiang Uygur Autonomous Region Natural Science Foundation (2022D01D69)
- Major Scientific Research Plan Cultivation Project of Xinjiang Medical University (No.XYD2024ZX02)
- Tianshan Talent Cultivation Plan for Young Top Talents Project of Xinjiang Uygur Autonomous Region (2024TSYCCX0103)
This publication has 34 references indexed in Scilit:
- Characterization of novel mouse esophageal squamous cell carcinoma cell lines and their utility as preclinical modelsCancer Letters, 2025
- The hallmarks of cancer immune evasionCancer Cell, 2024
- Cancer survival statistics in China 2019–2021: a multicenter, population-based studyJournal of the National Cancer Center, 2024
- Vimentin, inversely correlating with infiltration of CD8 + T lymphocytes, promotes nuclear translocation of PD-L1 in esophageal squamous cell carcinomaBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2024
- Rechallenge with immune checkpoint inhibitors for advanced esophageal squamous cell carcinomaInternational Immunopharmacology, 2024
- TRAF6 enhances PD-L1 expression through YAP1-TFCP2 signaling in melanomaCancer Letters, 2024
- Differential gene expression analysis pipelines and bioinformatic tools for the identification of specific biomarkers: A reviewComputational and Structural Biotechnology Journal, 2024
- Targeting MHC-I inhibitory pathways for cancer immunotherapyTrends in Immunology, 2024
- A membrane-associated MHC-I inhibitory axis for cancer immune evasionCell, 2023
- Advances and challenges in the treatment of esophageal cancerActa Pharmaceutica Sinica B, 2021